Skip to search formSkip to main contentSkip to account menu
  • Publications
  • Influence
Erlotinib in previously treated non-small-cell lung cancer.
TLDR
Elotinib can prolong survival in patients with non-small-cell lung cancer after first-line or second-line chemotherapy, and five percent of patients discontinued erlot inib because of toxic effects.
View on PubMed
Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.
TLDR
Treatment with pemetrexed resulted in clinically equivalent efficacy outcomes, but with significantly fewer side effects compared with docetaxel in the second-line treatment of patients with advanced NSCLC and should be considered a standard treatment option for second-liners when available.
View on PubMed
Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer
TLDR
Osimertinib had significantly greater efficacy than platinum therapy plus pemetrexed in patients with T790M‐positive advanced non‐small‐cell lung cancer (including those with CNS metastases) in whom disease had progressed during first‐line EGFR‐TKI therapy.
View on Wolters Kluwer
Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy.
TLDR
Treatment with docetaxel is associated with significant prolongation of survival, and at a dose of 75 mg/m(2), the benefits of docetAXel therapy outweigh the risks.
View on PubMed
Gene expression–based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study
TLDR
A large, training–testing, multi-site, blinded validation study to characterize the performance of several prognostic models based on gene expression for 442 lung adenocarcinomas, providing the largest available set of microarray data with extensive pathological and clinical annotation for lungAdenocARCinomas.
View on Nature
Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial
View on Elsevier
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
View on Elsevier
Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
TLDR
Postoperative cisplatin-based chemotherapy significantly improves survival in patients with non-small-cell lung cancer (NSCLC).
View on PubMed
Erlotinib in lung cancer - molecular and clinical predictors of outcome.
TLDR
Among patients with non-small-cell lung cancer who receive erlotinib, the presence of an EGFR mutation may increase responsiveness to the agent, but it is not indicative of a survival benefit.
View on PubMed
Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer.
TLDR
Adjuvant vinorelbine plus cisplatin has an acceptable level of toxicity and prolongs disease-free and overall survival among patients with completely resected early-stage non-small-cell lung cancer.
View on PubMed
...
...
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License